a method which calls to mind the methods of the tailors of Laputa.—I am, etc.,

W. H. LYLE

Dista Products Ltd., Liverpool

- 1 Asberg, M., *et al.*, *British Medical Journal*, 1971, 3, 331.
- 2 Kragh-Sorensen, P., Asberg, M., and Eggert-Hansen, C., *Lancet*, 1973, 1, 113.
- 3 Lyle, W. H., *et al.*, *Postgraduate Medical Journal*, 1974, 50, 282.

Malignant Hyperpyrexia

SIR,—I should like to make a few comments on your leading article (30 November, p. 488) on malignant hyperpyrexia. Denborough and Lovell¹ were the first to report a case of malignant hyperpyrexia in 1960. They followed this with a more detailed report in 1962,² well before Saidman *et al.* in 1964.³ However, Saidman *et al.* can claim to be the first to treat malignant hyperpyrexia successfully with the help of steroids. They cured a patient whose temperature had risen to 108.5°F (42.5°C) with an arterial pH of 6.82, and reduced his temperature within an hour to 97.2°F (36.2°C) using icepacks and prednisone.³

You imply that myotonia congenita is a myopathy that commonly underlies malignant hyperpyrexia. This is not so: the association between myotonia congenita and malignant hyperpyrexia is extremely rare. Saidman's case of malignant hyperpyrexia (No. 2 in his report) was described as suffering from a generalized muscle weakness diagnosed as myotonia congenita.³ However, no clinical sign of myotonia was mentioned, and muscle weakness is not a common sign of myotonia congenita. Histology at necropsy showed generalized polymyositis. Thus the diagnosis in this case is in doubt.

Harriman *et al.*⁴ reviewed patients that recovered from malignant hyperpyrexia and their relatives. The only clinical signs of myopathy that they found were hypertrophy and slight weakness of the lateral parts of the thigh and absent ankle jerks—no clinical sign of myotonia was seen nor was there any histological evidence. Certainly Britt *et al.*⁵ could find no evidence of myotonia in their investigations. Other reports^{7,8} confirm that myotonia congenita is not usually the underlying myopathy. To put things in perspective, King *et al.*⁹ have reported one patient who developed malignant hyperpyrexia who came from a family affected by myotonia congenita. None of the other 17 patients or their relatives who were investigated were affected by myotonia congenita.

It would not be surprising if there is a small rise in temperature associated with the generalized muscle spasm that sometimes follows the administration of suxamethonium to a patient with myotonia. Cody¹⁰ described such a case in which the temperature reached 99.4°F (37.5°C)—hardly characteristic of malignant hyperpyrexia. Reports of cases with clinical myotonia (both dystrophica myotonica and myotonia congenita) undergoing anaesthesia do not mention complications from pyrexia.¹¹⁻¹³ Thus there is one report of a patient with myotonia congenita developing malignant hyperpyrexia. The evidence at present suggests that this association may be purely one of chance rather than significance.—I am, etc.,

P. FURNISS

Norfolk and Norwich Hospital, Norwich

- 1 Denborough, M. A., and Lovell, R. R. H., *Lancet*, 1960, 2, 45.
- 2 Denborough, M. A., *et al.*, *British Journal of Anaesthesia*, 1962, 34, 395.
- 3 Saidman, L. J., Havard, E. S., and Eger, E. I., *Journal of the American Medical Association*, 1964, 190, 1029.
- 4 Harriman, D. G. F., Sumner, D. W., and Ellis, F. R., *Quarterly Journal of Medicine*, 1973, 42, 639.
- 5 Britt, B. A., Locher, W. G., and Kalow, W., *Canadian Anaesthetists' Society Journal*, 1969, 16, 89.
- 6 Barlow, H., and Isaacs, M. B., *British Journal of Anaesthesia*, 1970, 42, 1072.
- 7 La Cour, D., Juul-Jensen, P., and Reske-Nielsen, E., *Acta Anaesthesiologica Scandinavica*, 1971, 15, 299.
- 8 Steers, A. J. W., Tallack, J. A., and Thompson, D. E. A., *British Medical Journal*, 1970, 2, 341.
- 9 King, J. O., Denborough, M. A., and Zapf, P., *Lancet*, 1972, 1, 365.
- 10 Cody, J. R., *Anesthesiology*, 1968, 29, 159.
- 11 Kaufman, L., *Proceedings of the Royal Society of Medicine*, 1960, 53, 183.
- 12 McClelland, R. M. A., *British Journal of Anaesthesia*, 1960, 32, 81.
- 13 Thiel, R. E., *British Journal of Anaesthesia*, 1967, 39, 815.

Diagnostic Test for Multiple Sclerosis

SIR,—In refuting the specificity of the linoleic acid test for multiple sclerosis,¹ Mertin *et al.*² maintain that they have repeated the work "under conditions which were not . . . changed in any material respect." While it is true that one of us (B.K.S.) made the measurements upon which their paper is based, there were important differences.

(1) Absence of E.J.F. with his personal supervision of the animal supply.

(2) Failure of adequate checking for guinea-pig sensitization during the relevant November-December period. A major part of the trial was carried out during (influenza-ridden) December—when only one check was made. Indeed, Mertin *et al.*'s pretty, but largely irrelevant, fig. 2 serves mainly to show how checking lapsed after June, when E.J.F. relinquished control. Unfortunately, Professor A. M. Thomson was not able to give the time at which animal house precautions³ were allowed to lapse, though the need for them had long been known to Mr. E. A. Caspary.⁴

(3) The finding of occasional spontaneous sensitization to P.P.D. in concomitant macrophage migration inhibition tests carried out by Mr. D. Hughes⁵ on the stock of normal guinea-pigs used as the source of normal macrophages. This direct experimental evidence of presensitization, vital in the present context, is omitted from Mertin *et al.*'s presentation. Successful operation of the macrophage electrophoretic mobility (M.E.M.) test requires the use not only of Analor grade chemical reagents but also of a similar grade of the most complicated reagent of all, the macrophage cell.

(4) Use of P.P.D. as test antigen in place of thyroid¹—a substitution without importance if non-sensitized guinea-pigs are used as the source of macrophages but one which experimental test shows to lead to bizarre results if animals are presensitized.⁵

Mertin *et al.*, in quoting Shenton,³ stop short of reference to "certain other sources of error which may have been operating."³ For example, Professor Thomson was unable to give an assurance that detergents had not been reintroduced into the glassware cleaning process. This too may lead to random results (including those from duplicate specimens). A recent test carried out in another laboratory showed that merely drawing macrophages five or six times through a Decon-cleaned pipette—

perfectly adequate for other purposes—added one second to the migration time of the cells.

In experiments involving the M.E.M. test specimens have from the very beginning been randomized and presented to the observer in numbered bijou bottles^{6,7} so that it would require a paranormal feat of some magnitude on the part of B.K.S. to know upon which specimens to bring to bear his "subjective bias." In many family studies he did not, in fact, know which was the multiple sclerosis patient.

The consistency of the method is attested by the series of control figures published by Mr. Caspary⁷ and by Shenton *et al.*⁸ The latter (Mr. Hughes being a coauthor) have eliminated some of the "subjective element" in the measurements. For each result the statistical significance has been calculated (from the raw data) and with present expertise (B.K.S.) percentage differences as low as 7.8% correspond to a P value of <0.01 (as opposed to the 15% needed two or three years ago). Increasing accuracy has also been a feature of Mr. Caspary's own later results.

Finally, the result of just such a "double-blind" trial advocated by Mertin *et al.*, in which the observer does not know the provenance of the bloods from which his scrambled numbered bottles have been prepared, was published by Jenssen *et al.*⁹ on the same day as Mertin's denial. In a first series they clearly differentiated multiple sclerosis patients on the one hand from patients with other neurological diseases and normal subjects on the other. With increasing experience they reported (in a second series⁹) figures almost identical with those of Field *et al.*¹—a clear encouragement to those prepared to exercise the attention to detail that the method demands. It might be added that these authors had previously confirmed the cancer test¹¹ greeted (not unnaturally) with so much scepticism when it first appeared but now substantiated in several laboratories.¹²—We are, etc.,

E. J. FIELD
B. K. SHENTON

Department of Pathology,
Newcastle General Hospital,
Newcastle upon Tyne

- 1 Field, E. J., Shenton, B. K., and Joyce, G., *British Medical Journal*, 1974, 1, 412.
- 2 Mertin, J., *et al.*, *British Medical Journal*, 1974, 4, 567.
- 3 Shenton, B. K., and Caspary, E. A., *Lancet*, 1972, 1, 963.
- 4 Shenton, B. K., *et al.*, *British Medical Journal*, 1974, 4, 590.
- 5 Field, E. J., and Caspary, E. A., *Lancet*, 1970, 2, 1337.
- 6 Caspary, E. A., and Field, E. J., *British Medical Journal*, 1971, 2, 613.
- 7 Shenton, B. K., Hughes, D., and Field, E. J., *British Journal of Cancer*, 1973, 28, suppl. 1, 215.
- 8 Jenssen, H. L., *et al.*, *Lancet*, 1974, 2, 1327.
- 9 Jenssen, H. L., *et al.*, *British Medical Journal*, 1974, 4, 407.
- 11 Meyer-Rienecker, H., *et al.*, *Klinische Wochenschrift*, 1974, 52, 288.
- 12 Nature, 1973, 244, 130.

Pericarditis and Peritonitis Associated with Practolol Therapy

SIR,—There have been increasing reports of side effects of practolol, including pericarditis and "sclerosing or plastic peritonitis."¹ The following case may represent another of these unusual reactions.

A 48-year-old man was seen in February 1973. He had had palpitations for eight